RxDoctor Payments DataLook up a doctor →

Marc Riedl, MD

Allergy & Immunology · San Diego, CANPI 1285654889

Payments from drug & device makers

$903,105in general payments, 2019–2025

Across 628 payments — averaging $1438.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$200K
  • Pharming Healthcare, Inc.$188K
  • Shire North American Group Inc$154K
  • Takeda Pharmaceuticals U.S.A., Inc.$143K
  • Grifols USA, LLC$67K
  • Biocryst Pharmaceuticals, Inc.$45K
  • plus $105K from 20 others
$39,416in research payments, 2019–2025

Across 5 payments — averaging $7883.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$39K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$903,105 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$39,544
Medicare patients
160
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other allergy & immunology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →